Core Viewpoint - The company, Jiangsu Sihuan Biological Co., Ltd., anticipates a significant increase in revenue for the first half of 2025, despite reporting a net loss attributed to various operational challenges [1][2]. Financial Performance Summary - Expected operating revenue for the period is projected to be approximately 105.81 million yuan, representing a year-on-year growth of 70.12% to 79.57% [1]. - The net loss attributable to shareholders is estimated to be between 9 million to 13 million yuan, compared to a loss of 11.06 million yuan in the same period last year, indicating a decrease of 17.56% to 18.61% [1]. - The net loss after deducting non-recurring gains and losses is expected to be between 10 million to 14 million yuan, a decline of 42.75% to 1.96% compared to a loss of 9.81 million yuan last year [1]. - Basic earnings per share are projected to be between -0.0126 yuan and -0.0087 yuan, compared to -0.0107 yuan per share in the previous year [1]. Reasons for Performance Changes - The primary reason for the company's losses is a slight decline in revenue from its subsidiary, Beijing Sihuan Biological Pharmaceutical Co., Ltd., along with increased management expenses due to legal fees related to a securities fraud case [2]. - Conversely, the increase in operating revenue is attributed to a strategic cooperation agreement between its wholly-owned subsidiary, Jiangsu Chenwei Ecological Park Technology Co., Ltd., and Jiangyin Xinganfa Trading Co., Ltd., leading to a substantial rise in sales of seedlings [2]. Other Relevant Information - The performance forecast is based on preliminary estimates from the company's finance department, with final figures to be confirmed in the official half-year report for 2025 [2].